Few countries in Europe have limited the use of Moderna's vaccine
Advisers to the U.S. Food and Drug Administration (FDA) unanimously recommended the authorization of Moderna Inc's COVID-19 vaccine for children aged between 6 to 17 years. Around 77 million people aged 18 and older in the United States have received at least a two-dose course of Moderna's vaccine. The committee of outside experts is scheduled to consider the Moderna vaccine for children under six and Pfizer and BioNTech's COVID shot for children below 5 - and in both cases, as young as six months. According to the data from the U.S. Centres for Disease Control and Prevention, only around 30% of those between the ages of 5 to 11 and 60% of 12- to 17-year-olds are fully vaccinated in the United States.
There are concerns that the Moderna vaccine, which is a higher dose than the Pfizer/BioNTech shot, may cause heart inflammation known as myocarditis and pericarditis at higher rates, primarily in younger males. Few countries in Europe have limited the use of Moderna's vaccine for younger age groups due to the same reason. U.S. regulators suggested that Moderna's vaccine may have a higher risk of heart inflammation in young men but also observed that the findings were not consistent across various safety databases and were not statistically significant.